Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 49Pancreatic Neoplasms 33Prostatic Neoplasms 31Brain Neoplasms 28Lung Neoplasms 26Neoplasm Metastasis 24Melanoma 21Carcinoma, Hepatocellular 20Breast Neoplasms 16Carcinoma, Renal Cell 12Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Neoplasms 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 5Recurrence 5Head and Neck Neoplasms 5Glioblastoma 5Adenocarcinoma of Lung 5Sarcoma 4Liver Neoplasms 4Kidney Neoplasms 4Uterine Cervical Neoplasms 3NSCLC 3Clear-cell metastatic renal cell carcinoma 3Cholangiocarcinoma 3Uveal Melanoma 2Unresectable Locally Recurrent Rectal Cancer 2Rectal Neoplasms 2Ovarian Neoplasms 2

Interventions

Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Paclitaxel 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Bortezomib 2vandetanib 1umbralisib 1ublituximab 1regorafenib 1pomalidomide 1pembrolizumab 1nilotinib 1marizomib 1lutetium Lu 177 dotatate 1grapiprant 1fludarabine phosphate 1fludarabine 1durvalumab 1cemiplimab 1carotuximab 1axicabtagene ciloleucel 1avelumab 1Thioctic Acid 1Tamoxifen 1Receptors, Interleukin-6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × Radiosurgery × Clear all
NCT04974671 2025-12-04

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Yale University

Phase 2 Recruiting
30 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡